{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:24:43Z","timestamp":1794252283470,"version":"4.9.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009129","name":"Evidence Synthesis Programme","doi-asserted-by":"publisher","award":["NIHR153779"],"award-info":[{"award-number":["NIHR153779"]}],"id":[{"id":"10.13039\/501100009129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40273-025-01559-z","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:31:51Z","timestamp":1762187511000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-3689","authenticated-orcid":false,"given":"Matthew","family":"Walton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5901-1101","authenticated-orcid":false,"given":"Nyanar J.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-1493","authenticated-orcid":false,"given":"Mark","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4114-2227","authenticated-orcid":false,"given":"Chinyereugo","family":"Umemneku-Chikere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-2709","authenticated-orcid":false,"given":"Sarah J.","family":"Nevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-1099","authenticated-orcid":false,"given":"Helen","family":"Fulbright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Yew","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-2581","authenticated-orcid":false,"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-0512","authenticated-orcid":false,"given":"Rachel","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":false,"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"1559_CR1","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. 4 April 2013. Available from: http:\/\/publications.nice.org.uk\/pmg9. Accessed 25 Feb 2025."},{"key":"1559_CR2","unstructured":"National Institute for Health and Care Excellence. Interim process and methods of the highly specialised technologies programme (updated to reflect 2017 changes). NICE; 2017."},{"key":"1559_CR3","unstructured":"National Institute for H, Care E. Avalglucosidase alfa for treating Pompe disease. NICE technology appraisal guidance 821. England: National Institute for Health and Care Excellence (NICE); 2022."},{"key":"1559_CR4","unstructured":"National Institute for H, Care E. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease. NICE technology appraisal guidance 912. England: National Institute for Health and Care Excellence (NICE); 2023."},{"key":"1559_CR5","unstructured":"Therapeutics S. A gene transfer study for late-onset Pompe disease (RESOLUTE). 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04093349. Accessed 20 Nov 2024."},{"key":"1559_CR6","unstructured":"Inc G. Evaluation of the safety and efficacy of infantile-onset Pompe disease gene therapy drug. 2023. Available from: https:\/\/clinicaltrials.gov\/show\/NCT05793307. Accessed 20 Nov 2024."},{"key":"1559_CR7","unstructured":"Therapies AG. Gene transfer study in patients with late onset Pompe disease. 2019. Available from: https:\/\/clinicaltrials.gov\/show\/NCT04174105. Accessed 20 Nov 2024."},{"key":"1559_CR8","unstructured":"Inc. AB. AAV2\/8-LSPhGAA (ACTUS-101) in late-onset Pompe disease. 2018. Available from: https:\/\/clinicaltrials.gov\/show\/NCT03533673. Accessed 20 Nov 2024."},{"key":"1559_CR9","unstructured":"Florida Uo. Re-administration of intramuscular AAV9 in patients with late-onset Pompe disease. 2014. Available from: https:\/\/clinicaltrials.gov\/show\/NCT02240407. Accessed 20 Nov 2024."},{"key":"1559_CR10","unstructured":"Hospital H. Evaluation of the safety, tolerability and efficacy of gene therapy drug for late onset Pompe disease (LOPD). 2023. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06178432. Accessed 20 Nov 2024."},{"key":"1559_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00177","volume":"6","author":"JA Lim","year":"2014","unstructured":"Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177.","journal-title":"Front Aging Neurosci"},{"key":"1559_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ODRR.S69109","volume":"7","author":"JF Cabello","year":"2017","unstructured":"Cabello JF, Marsden D. Pompe disease: clinical perspectives. Orphan Drugs Res Rev. 2017;7:1\u201310.","journal-title":"Orphan Drugs Res Rev"},{"key":"1559_CR13","unstructured":"National Institutes of Health. Pompe disease. n.d. Available from: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/pompe-disease. Accessed 13 Dec 2024."},{"issue":"1\u20132","key":"1559_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","volume":"119","author":"A van der Ploeg","year":"2016","unstructured":"van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, et al. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY study. Mol Genet Metab. 2016;119(1\u20132):115\u201323.","journal-title":"Mol Genet Metab"},{"issue":"15","key":"1559_CR15","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362(15):1396\u2013406.","journal-title":"N Engl J Med"},{"issue":"6","key":"1559_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, Laforet P, Angelini C, Lachmann RH, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24(6):768-e31.","journal-title":"Eur J Neurol"},{"key":"1559_CR17","volume-title":"National Specialist Commissioning Advisory Group annual report 2006\/07","author":"Department of Health","year":"2007","unstructured":"Department of Health. National Specialist Commissioning Advisory Group annual report 2006\/07. London: Department of Health; 2007."},{"key":"1559_CR18","unstructured":"Deegan P. Guidelines for the investigation and management of late onset acid maltase deficiency (type II glycogen storage disease\/Pompe disease). Version 3 2007."},{"key":"1559_CR19","volume-title":"Letter: National designation and funding of the service for patients with lysosomal storage disorders","author":"J Stallibrass","year":"2004","unstructured":"Stallibrass J. Letter: National designation and funding of the service for patients with lysosomal storage disorders. London: Department of Health; 2004."},{"key":"1559_CR20","unstructured":"National Specialised Commissioning Advisory Group. Lysosomal storage disorders: policy on the funding of enzyme replacement therapy and substrate reduction therapy 2008. Available from: https:\/\/web.archive.org\/web\/20090409234844\/http:\/\/www.ncg.nhs.uk\/documents\/lsd_nscag_policy_on_funding_of_ert_and_lsd-280307.pdf. Accessed 1 Mar 2025."},{"key":"1559_CR21","doi-asserted-by":"crossref","unstructured":"Walton M, Deng NJ, Corbett M, Umemneku-Chikere C, Nevitt S, Fulbright H, et al. The cost-effectiveness of enzyme replacement therapies versus best supportive care for treating late onset Pompe disease in the UK NHS. Eur J Health Econ. 2025. (accepted)","DOI":"10.1007\/s10198-025-01868-2"},{"issue":"1","key":"1559_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13023-025-03981-0","volume":"20","author":"M Corbett","year":"2025","unstructured":"Corbett M, Umemneku-Chikere C, Nevitt S, Deng NJ, Walton M, Fulbright H, et al. Enzyme replacement therapy compared with best supportive care for the treatment of Pompe disease: a systematic review and network meta-analysis. Orphanet J Rare Dis. 2025;20(1):14.","journal-title":"Orphanet J Rare Dis"},{"key":"1559_CR23","unstructured":"National Institute for Health and Care Excellence. Highly specialised technology appraisal. Catidarsagene autotemcel for treating metachromatic leukodystrophy [HST18]. 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/hst18. Accessed 23 Nov 2024."},{"issue":"6","key":"1559_CR24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40258-021-00663-3","volume":"19","author":"S Martin","year":"2021","unstructured":"Martin S, Lomas J, Claxton K, Longo F. How effective is marginal healthcare expenditure? New evidence from England for 2003\/04 to 2012\/13. Appl Health Econ Health. 2021;19(6):885\u2013903.","journal-title":"Appl Health Econ Health"},{"issue":"4","key":"1559_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40258-022-00723-2","volume":"20","author":"S Martin","year":"2022","unstructured":"Martin S, Claxton K, Lomas J, Longo F. How responsive is mortality to locally administered healthcare expenditure? Estimates for England for 2014\/15. Appl Health Econ Health Policy. 2022;20(4):557\u201372.","journal-title":"Appl Health Econ Health Policy"},{"issue":"11","key":"1559_CR26","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/hec.4393","volume":"30","author":"B Woods","year":"2021","unstructured":"Woods B, Fox A, Sculpher M, Claxton K. Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. Health Econ. 2021;30(11):2649\u201366.","journal-title":"Health Econ"},{"key":"1559_CR27","unstructured":"National Institute for Health and Care Excellence. Highly Specialised Technology Appraisal. Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann\u2013Pick disease) type AB and type By [HST32]. 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/hst32. Accessed 28 Aug 2025."},{"key":"1559_CR28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2147\/PPA.S416226","volume":"17","author":"YC Gu","year":"2023","unstructured":"Gu YC, Wang AQ, Tang H, Wang HD, Jiang YJ, Jin CL, et al. Comparison of rare and common diseases in the setting of healthcare priorities: evidence of social preferences based on a systematic review. Patient Prefer Adher. 2023;17:1783\u201397.","journal-title":"Patient Prefer Adher"},{"key":"1559_CR29","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal. Efgartigimod for treating generalised myasthenia gravis [ID 4003]. 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10986. Accessed 23 June 2025."},{"key":"1559_CR30","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over [TA1051]. 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/TA1051. Accessed 23 Mar 2025."},{"key":"1559_CR31","doi-asserted-by":"crossref","unstructured":"Department of Health and Social Care. Fit for the future: 10-year health plan for England. London; 2025.","DOI":"10.12968\/jokc.2025.10.5.212"},{"issue":"4","key":"1559_CR32","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/hec.4795","volume":"33","author":"B Woods","year":"2024","unstructured":"Woods B, Lomas J, Sculpher M, Weatherly H, Claxton K. Achieving dynamic efficiency in pharmaceutical innovation: identifying the optimal share of value and payments required. Health Econ. 2024;33(4):804\u201319.","journal-title":"Health Econ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01559-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01559-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01559-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:35:15Z","timestamp":1769783715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01559-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01559-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data contributing to this work were derived from a systematic review of published studies, which can be found in Corbett et al. [\n                      \n                      ]","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualisation: MW, RH, NJD, MC, CUC, SN; CYT, RL, RC, RH; Methodology: MW, RH; Formal analysis and investigation: MW, RH, NJD, HF, MC, CUC, SN; Clinical validation: CYT, RL; Writing \u2013 original draft preparation: MW, RH, NJD; Writing \u2013 review and editing: MW, RH, NJD, MC, SN, CYT, RL; Funding acquisition and supervision: RH, RC.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}